CHARACTERIZATION OF 2 DIFFERENTLY GLYCOSYLATED MOLECULAR-SPECIES OF YEAST-DERIVED HEPATITIS-B VACCINE CARRYING THE PRE-S2 REGION

被引:1
|
作者
KOBAYASHI, M [1 ]
ASANO, T [1 ]
OHFUNE, K [1 ]
KATO, K [1 ]
机构
[1] TAKEDA CHEM IND LTD,HIKARI PLANT,YODOGAWA KU,OSAKA 532,JAPAN
关键词
HEPATITIS-B VACCINE; S + PRE-S2; SUGAR CHAINS; IMMUNOGENICITY;
D O I
10.1016/0168-1656(92)90003-R
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Modified hepatitis B virus surface antigen M protein particles (HBsAg M-P31c) produced in yeast is mainly composed of two differently glycosylated proteins, GP37 and GP34. GP37 has an N-linked sugar chain and O-linked sugar chains; and GP34 has an N-linked sugar chain bound to the peptide backbone P31. Although M-P31c vaccine elicits both anti-S and anti-pre-S2 antibodies, whether there are any differences between GP37 and GP34 in the ability to elicit these antibodies is still unknown. To clarify this issue, we prepared particles which were composed solely of GP37 or GP34 by affinity chromatography, using polymerized human serum albumin as a ligand and digestion with alpha-mannosidase. We also prepared particles composed solely of P31 by successive digestion with alpha-mannosidase and endo-beta-N-acetylglycosaminidase H. The vaccines derived from these three kinds of particles elicited both anti-S and anti-pre-S2 antibodies in mice to the same extent as the original M-P31c vaccine. These results suggest that the N- and O-linked sugar chains of M-P31c component proteins produced in the host yeast cells have no effect on the ability to elicit anti-S and anti-pre-S2 antibodies and that there are no differences with respect to antibody response in mice between the two major components of M-P31c, GP37 and GP34.
引用
收藏
页码:155 / 162
页数:8
相关论文
共 50 条
  • [1] RECOMBINANT HEPATITIS-B VIRUS SURFACE-ANTIGEN CARRYING THE PRE-S2 REGION DERIVED FROM YEAST - PURIFICATION AND CHARACTERIZATION
    KOBAYASHI, M
    ASANO, T
    UTSUNOMIYA, M
    ITOH, Y
    FUJISAWA, Y
    NISHIMURA, O
    KATO, K
    KAKINUMA, A
    JOURNAL OF BIOTECHNOLOGY, 1988, 8 (01) : 1 - 21
  • [2] THE OLIGOSACCHARIDES IN A RECOMBINANT HEPATITIS-B VIRUS SURFACE-ANTIGEN (HBSAG) CARRYING THE PRE-S2 REGION DERIVED FROM YEAST
    KOBAYASHI, M
    BAN, J
    ASANO, T
    UTSUNOMIYA, M
    KUSUMOTO, S
    NISHI, K
    KATO, K
    FEBS LETTERS, 1992, 302 (02) : 129 - 132
  • [3] CHARACTERISTICS OF PRE-S2 REGION OF HEPATITIS-B VIRUS
    LO, SCJ
    CHEN, ML
    CHIEN, ML
    LEE, YHW
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1986, 135 (02) : 382 - 388
  • [4] IMMUNOGENICITY OF YEAST-DERIVED HEPATITIS-B VACCINE FROM 2 DIFFERENT PRODUCERS
    DAHLHANSEN, E
    SIEBKE, JC
    FROLAND, SS
    DEGRE, M
    EPIDEMIOLOGY AND INFECTION, 1990, 104 (01): : 143 - 149
  • [5] PRE-S2 ANTIBODIES IN HEPATITIS-B
    AIHARA, S
    ISE, I
    TSUDA, F
    TAKAI, E
    MACHIDA, A
    MIYAKAWA, Y
    LANCET, 1986, 2 (8521-2): : 1457 - 1458
  • [6] IMMUNOGENICITY OF A NEW TYPE OF YEAST-DERIVED HEPATITIS-B VACCINE CONSISTING OF M (PRE-S2+S) PROTEIN PARTICLES
    HAZAMA, M
    TAKAOKI, M
    OHFUNE, K
    HINUMA, S
    FUJISAWA, Y
    VACCINE, 1989, 7 (06) : 567 - 573
  • [7] SIGNIFICANCE OF PRE-S2 PEPTIDE OF HEPATITIS-B VIRUS - SHOULD IT BE IN THE VACCINE
    HELLSTROM, UB
    SYLVAN, SPE
    PROGRESS IN MEDICAL VIROLOGY, 1988, 35 : 76 - 106
  • [8] COMPARISON OF IMMUNOGENICITY OF 2 YEAST-DERIVED RECOMBINANT HEPATITIS-B VACCINES
    HAMMOND, GW
    PARKER, J
    MIMMS, L
    TATE, R
    SEKLA, L
    MINUK, G
    VACCINE, 1991, 9 (02) : 97 - 100
  • [9] THE PRE-S2 REGION OF HEPATITIS-B VIRUS - MORE QUESTIONS THAN ANSWERS
    GERBER, MA
    THUNG, SN
    HEPATOLOGY, 1989, 9 (02) : 328 - 330
  • [10] GENETIC CONSERVATION WITHIN SUBTYPES IN THE HEPATITIS-B VIRUS PRE-S2 REGION
    KIDDLJUNGGREN, K
    COUROUCE, AM
    OBERG, M
    KIDD, AH
    JOURNAL OF GENERAL VIROLOGY, 1994, 75 : 1485 - 1490